Literature DB >> 26695345

Primary cutaneous CD30+ anaplastic large cell lymphoma treated with radiotherapy and methotrexate with development of xanthomas at the sites of prior disease.

Lucía Turrión-Merino1, Silvia Perez-Gala1, Eva Hermosa-Zarza1, Marta Urech-García-de-la-Vega1, Rosario Carrillo-Guijón2, Pedro Jaén-Olasolo1.   

Abstract

Primary cutaneous anaplastic large cell lymphoma is a rare type of cutaneous T-cell lymphoma, and the involvement of the ocular adnexa is extremely rare. Secondary xanthoma-like changes after radiation therapy or chemotherapy have been rarely reported in association with large-cell T-cell anaplastic lymphoma. We report one case of a primary C-anaplastic large cell lymphoma affecting the eyelid with fast progression with multiple nodules in various anatomic sites and development of xanthoma-like lesions after treatment.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  anaplastic large cell lymphoma; methotrexate; ocular adnexa; radiotherapy; xanthoma

Mesh:

Substances:

Year:  2016        PMID: 26695345     DOI: 10.1111/cup.12661

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  3 in total

Review 1.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

2.  CD30+ Cutaneous Anaplastic Large-Cell Lymphoma of the Upper Eyelid: A Case Report.

Authors:  Stéphanie Olivier; Claire Dachelet; Ivan Theate; Isabelle Tromme; Marie Baeck
Journal:  Case Rep Dermatol       Date:  2017-10-20

3.  Primary cutaneous CD 30 (+) ALK (-) anaplastic large cell lymphoma with dermoscopic findings: a case report.

Authors:  Tugba K Uzuncakmak; Necmettin Akdeniz; Ayse S Karadag; Secil Taskin; Ebru I Zemheri; Giuseppe Argenziano
Journal:  Dermatol Pract Concept       Date:  2017-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.